<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364608</url>
  </required_header>
  <id_info>
    <org_study_id>D6930C00001</org_study_id>
    <nct_id>NCT03364608</nct_id>
  </id_info>
  <brief_title>Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma</brief_title>
  <official_title>A Randomized, Double-blind, Single Dose, Placebo-controlled, 5-Period, 5-Treatment, Crossover, Multi-center, Dose-ranging Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Mild to Moderate Asthma (ANTORA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, single-dose, placebo-controlled, 5-period, 5-treatment,
      crossover, multi-center study to assess the bronchodilatory effect and safety of 2 dose
      levels of Albuterol Sulfate Pressurized Inhalation Suspension (hereafter referred to as AS
      MDI), 90 μg and 180 μg, compared with placebo for AS MDI (hereafter referred to as Placebo
      MDI) and open-label Proventil® hydrofluoroalkane (HFA; hereafter referred to as Proventil) 90
      μg and 180 μg in adult and adolescent subjects with mild to moderate asthma. This study
      design utilizes 10 treatment sequences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 5-period crossover study. Each Treatment Period is 1 day. Subjects will receive a
      single dose of randomized study drug at each of the 5 Treatment Visits (Visits 2, 3, 4, 5,
      and 6), with a 3- to 7-day Washout Period between Treatment Visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">March 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in FEV1 AUC0-6</measure>
    <time_frame>Over 6 hours post dose on Day 1</time_frame>
    <description>Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-6 (Area under the curve from 0 to 6 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, 240, 300, and 360 minutes post-dose) normalized for length of follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FEV1 AUC0-4</measure>
    <time_frame>Over 4 hours post dose on Day 1</time_frame>
    <description>Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-4 (Area under the curve from 0 to 4 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, and 240 minutes post-dose) normalized for length of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1</measure>
    <time_frame>Over 6 hours post dose on Day 1</time_frame>
    <description>Peak Change from baseline in FEV1 (Forced expiratory volume in 1 second)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>• AS MDI 90 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(2 actuations of 45 µg/actuation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>• AS MDI 180 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(2 actuations of 90 µg/actuation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>• Placebo MDI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(2 actuations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>• Proventil 90 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(1 actuation of 90 µg/actuation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>• Proventil 180 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(2 actuations of 90 µg/actuation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS MDI 90 μg</intervention_name>
    <description>AS MDI 90 μg (2 actuations of 45 μg/actuation)</description>
    <arm_group_label>• AS MDI 90 µg</arm_group_label>
    <other_name>AS MDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AS MDI 180 µg</intervention_name>
    <description>AS MDI 180 μg (2 actuations of 90 μg/actuation)</description>
    <arm_group_label>• AS MDI 180 µg</arm_group_label>
    <other_name>AS MDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo MDI</intervention_name>
    <description>Placebo MDI (2 actuations)</description>
    <arm_group_label>• Placebo MDI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proventil 90 μg</intervention_name>
    <description>Proventil 90 μg (1 actuation of 90 μg/actuation)</description>
    <arm_group_label>• Proventil 90 µg</arm_group_label>
    <other_name>Proventil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proventil 180 μg</intervention_name>
    <description>Proventil 180 μg (2 actuations of 90 μg/actuation)</description>
    <arm_group_label>• Proventil 180 µg</arm_group_label>
    <other_name>Proventil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Are at least 12 years of age and no older than 65 years

          -  Have stable (for 6 months) physician-diagnosed asthma with historical documentation of
             the diagnosis

          -  Must be receiving 1 of the following required inhaled asthma therapies listed below
             for at least the last 30 days; Only SABA, which is used as needed for rescue, or Low
             to medium doses of ICS (alone or in combination with LABA), used regularly as
             maintenance asthma therapy

          -  Demonstrate acceptable spirometry performance (ie, meet American Thoracic Society
             [ATS]/European Respiratory Society [ERS] acceptability/repeatability criteria

          -  Pre-bronchodilator FEV1 of ≥40 to &lt;90% predicted normal value after withholding SABA
             for ≥6 hours

          -  Confirmed FEV1 reversibility to Ventolin, defined as a post-Ventolin increase in FEV1
             of ≥15%

          -  only 2 reversibility testing attempts are allowed

        Exclusion Criteria:

          -  Chronic obstructive pulmonary disease or other significant lung disease (eg, chronic
             bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or
             bronchopulmonary dysplasia)

          -  Oral corticosteroid use (any dose) within 6 weeks

          -  Current smokers, former smokers with &gt;10 pack-years history, or former smokers who
             stopped smoking &lt;6 months (including all forms of tobacco, e-cigarettes [vaping], and
             marijuana)

          -  Life-threatening asthma as defined as any history of significant asthma episode(s)
             requiring intubation associated with hypercapnia, respiratory arrest, hypoxic
             seizures, or asthma-related syncopal episode(s)

          -  Historical or current evidence of a clinically significant disease

          -  Cancer not in complete remission for at least 5 years

          -  Hospitalized for psychiatric disorder or attempted suicide within 1 year

          -  Unable to abstain from protocol-defined prohibited medications during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <zip>90274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=14724&amp;filename=PT007001_Protocol_Redacted_PDFA.pdf</url>
    <description>Protocol</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=14724&amp;filename=PT007001_SAP_Redacted_PDFA.pdf</url>
    <description>Statistical Analysis Plan (SAP)</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>July 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2019</results_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03364608/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT03364608/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 10 sites in the United States, from December 2017 to March 2018. The study was anticipated to run for at least 23 days but not to exceed 68 days.</recruitment_details>
      <pre_assignment_details>Subjects were randomized into one of 10 treatment sequences. Each sequence comprised all 5 treatments included in this study (ie, AS MDI 90 μg, AS MDI 180 μg, Placebo MDI, Proventil 90 μg, and Proventil 180 μg) in a randomized order</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects</title>
          <description>ITT Analysis set</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo MDI</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>AS MDI 90 µg</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>AS MDI 180 µg</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Proventil 90 µg</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Proventil 180 µg</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall number of Baseline Participants is from the Safety set.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Safety Set</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Safety Set</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Safety Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in FEV1 AUC0-6</title>
        <description>Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-6 (Area under the curve from 0 to 6 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, 240, 300, and 360 minutes post-dose) normalized for length of follow up.</description>
        <time_frame>Over 6 hours post dose on Day 1</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>AS MDI 180 µg</title>
            <description>(2 actuations of 90 µg/actuation)</description>
          </group>
          <group group_id="O2">
            <title>AS MDI 90 µg</title>
            <description>(2 actuations of 45 µg/actuation)</description>
          </group>
          <group group_id="O3">
            <title>Proventil 180 µg</title>
            <description>(2 actuations of 90 µg/actuation)</description>
          </group>
          <group group_id="O4">
            <title>Proventil 90 µg</title>
            <description>(1 actuation of 90 µg/actuation)</description>
          </group>
          <group group_id="O5">
            <title>Placebo MDI</title>
            <description>(2 actuations)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 AUC0-6</title>
          <description>Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-6 (Area under the curve from 0 to 6 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, 240, 300, and 360 minutes post-dose) normalized for length of follow up.</description>
          <population>mITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.266" lower_limit="0.219" upper_limit="0.313"/>
                    <measurement group_id="O2" value="0.203" lower_limit="0.156" upper_limit="0.251"/>
                    <measurement group_id="O3" value="0.282" lower_limit="0.234" upper_limit="0.329"/>
                    <measurement group_id="O4" value="0.240" lower_limit="0.193" upper_limit="0.288"/>
                    <measurement group_id="O5" value="0.070" lower_limit="0.022" upper_limit="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FEV1 AUC0-4</title>
        <description>Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-4 (Area under the curve from 0 to 4 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, and 240 minutes post-dose) normalized for length of follow up.</description>
        <time_frame>Over 4 hours post dose on Day 1</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>AS MDI 180 µg</title>
            <description>(2 actuations of 90 µg/actuation)</description>
          </group>
          <group group_id="O2">
            <title>AS MDI 90 µg</title>
            <description>(2 actuations of 45 µg/actuation)</description>
          </group>
          <group group_id="O3">
            <title>Proventil 180 µg</title>
            <description>(2 actuations of 90 µg/actuation)</description>
          </group>
          <group group_id="O4">
            <title>Proventil 90 µg</title>
            <description>(1 actuation of 90 µg/actuation)</description>
          </group>
          <group group_id="O5">
            <title>Placebo MDI</title>
            <description>(2 actuations)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 AUC0-4</title>
          <description>Change from baseline in FEV1 (Forced expiratory volume in 1 second) AUC0-4 (Area under the curve from 0 to 4 hours) (spirometry will be obtained at 5, 15, 30, 45, 60, 120, 180, and 240 minutes post-dose) normalized for length of follow up.</description>
          <population>mITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.331" lower_limit="0.280" upper_limit="0.381"/>
                    <measurement group_id="O2" value="0.263" lower_limit="0.213" upper_limit="0.313"/>
                    <measurement group_id="O3" value="0.349" lower_limit="0.299" upper_limit="0.400"/>
                    <measurement group_id="O4" value="0.297" lower_limit="0.247" upper_limit="0.348"/>
                    <measurement group_id="O5" value="0.080" lower_limit="0.030" upper_limit="0.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1</title>
        <description>Peak Change from baseline in FEV1 (Forced expiratory volume in 1 second)</description>
        <time_frame>Over 6 hours post dose on Day 1</time_frame>
        <population>mITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>AS MDI 180 µg</title>
            <description>(2 actuations of 90 µg/actuation)</description>
          </group>
          <group group_id="O2">
            <title>AS MDI 90 µg</title>
            <description>(2 actuations of 45 µg/actuation)</description>
          </group>
          <group group_id="O3">
            <title>Proventil 180 µg</title>
            <description>(2 actuations of 90 µg/actuation)</description>
          </group>
          <group group_id="O4">
            <title>Proventil 90 µg</title>
            <description>(1 actuation of 90 µg/actuation)</description>
          </group>
          <group group_id="O5">
            <title>Placebo MDI</title>
            <description>(2 actuations)</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1</title>
          <description>Peak Change from baseline in FEV1 (Forced expiratory volume in 1 second)</description>
          <population>mITT Population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.509" lower_limit="0.451" upper_limit="0.567"/>
                    <measurement group_id="O2" value="0.433" lower_limit="0.375" upper_limit="0.491"/>
                    <measurement group_id="O3" value="0.516" lower_limit="0.458" upper_limit="0.574"/>
                    <measurement group_id="O4" value="0.472" lower_limit="0.414" upper_limit="0.530"/>
                    <measurement group_id="O5" value="0.233" lower_limit="0.176" upper_limit="0.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed informed consent throughout the treatment period and up to 14 days following the last dose of study drug</time_frame>
      <desc>Serious Adverse Events were collected from the time the subject signed informed consent throughout the treatment period and up to approximately 68 days, which includes screening and follow up (3-7 days after last dose of study drug).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo MDI</title>
          <description>(2 actuations)</description>
        </group>
        <group group_id="E2">
          <title>AS MDI 90 µg</title>
          <description>(2 actuations of 45 µg/actuation)</description>
        </group>
        <group group_id="E3">
          <title>Proventil 180 µg</title>
          <description>(2 actuations of 90 µg/actuation)</description>
        </group>
        <group group_id="E4">
          <title>Proventil 90 µg</title>
          <description>(1 actuation of 90 µg/actuation)</description>
        </group>
        <group group_id="E5">
          <title>• Proventil 180 µg</title>
          <description>(2 actuations of 90 µg/actuation)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc, a Member of the AstraZeneca Group</organization>
      <phone>9739750321</phone>
      <email>Colin.Reisner@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

